- Home
- CZR vs GH Comparison
CZR vs GH Comparison
Compare CZR & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CZR
- GH
- Stock Information
- Founded
- CZR 1937
- GH 2011
- Country
- CZR United States
- GH United States
- Employees
- CZR N/A
- GH N/A
- Industry
- CZR Hotels/Resorts
- GH Medical Specialities
- Sector
- CZR Consumer Discretionary
- GH Health Care
- Exchange
- CZR Nasdaq
- GH Nasdaq
- Market Cap
- CZR 5.4B
- GH 5.5B
- IPO Year
- CZR 1989
- GH 2018
- Fundamental
- Price
- CZR $28.03
- GH $41.72
- Analyst Decision
- CZR Strong Buy
- GH Strong Buy
- Analyst Count
- CZR 13
- GH 21
- Target Price
- CZR $44.23
- GH $52.81
- AVG Volume (30 Days)
- CZR 5.6M
- GH 2.7M
- Earning Date
- CZR 04-29-2025
- GH 04-30-2025
- Dividend Yield
- CZR N/A
- GH N/A
- EPS Growth
- CZR N/A
- GH N/A
- EPS
- CZR N/A
- GH N/A
- Revenue
- CZR $11,297,000,000.00
- GH $773,996,000.00
- Revenue This Year
- CZR $3.74
- GH $19.53
- Revenue Next Year
- CZR $2.51
- GH $21.92
- P/E Ratio
- CZR N/A
- GH N/A
- Revenue Growth
- CZR N/A
- GH 28.20
- 52 Week Low
- CZR $21.40
- GH $18.01
- 52 Week High
- CZR $45.93
- GH $52.92
- Technical
- Relative Strength Index (RSI)
- CZR 55.37
- GH 43.79
- Support Level
- CZR $26.72
- GH $38.86
- Resistance Level
- CZR $28.40
- GH $52.92
- Average True Range (ATR)
- CZR 1.19
- GH 2.91
- MACD
- CZR 0.20
- GH -0.74
- Stochastic Oscillator
- CZR 76.07
- GH 20.34
About CZR Caesars Entertainment Inc.
Caesars Entertainment includes about 50 domestic gaming properties across the Las Vegas (49% of 2024 EBITDAR before corporate expenses) and regional (46%) markets. Additionally, the company hosts managed properties and digital assets that produced marginal EBITDA in 2024. Caesars' US presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the US portion of William Hill (it sold the international operation in 2022), a digital sports betting platform.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.